Literature DB >> 16793694

Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome.

P M Bath1, A Blann, N Smith, R J Butterworth.   

Abstract

Although ischaemic stroke is associated with accentuated platelet function, it remains unclear whether this applies to all sub-types, especially lacunar infarcts, which differ from cortical infarction in their patho-aetiology. Similarly, conflicting evidence suggests that haemorrhagic stroke may, or may not, be associated with a hypothrombotic state. Levels of von Willebrand factor (vWF), fibrinogen, and P-selectin were measured within 48 h of ictus in 163 patients with acute ischaemic stroke and 40 patients with acute primary intracerebral haemorrhage, and 33 age, gender and race matched-controls. vW F (IU/dl) was significantly increased in both cortical and lacunar ischaemic stroke, and haemorrhagic stroke, as compared with controls, median (semiquartile range): 158 (25) vs 144 (19) vs 147 (24) vs 114 (16), respectively. Similarly, fibrinogen (g/litre) was increased: 4.80 (0.90) vs 4.65 (0.70) vs 4.35 (0.83) vs 3.70 (0.70). In contrast, soluble P-selectin (ng/ml) was increased in cortical stroke as compared with lacunar infraction patients or controls: 408 (101) vs 300 (108) vs 324 (121), respectively; P-selectin was not increased in haemorrhagic stroke, 360 (153). Both vW F and fibrinogen correlated with 3-month functional outcome (modified Rankin score): r = 0.371 (2 P = 0.0006), and r = 0.195 (2 P = 0.042), respectively; however, P-selectin was not associated with outcome: r = 0.188 (2 P = 0.084). The results suggest that increases in vW F and fibrinogen in all types of stroke reflect an acute phase response; in contrast, increased soluble P-selectin levels in cortical stroke, but not lacunar infarction, suggest that platelets contribute to the patho-aetiology of some subtypes of ischaemic stroke.

Entities:  

Year:  1998        PMID: 16793694     DOI: 10.1080/09537109876618

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  18 in total

1.  Clinical role of von Willebrand factor in acute ischemic stroke.

Authors:  Marija Menih; Miljenko Križmarić; Tanja Hojs Fabjan
Journal:  Wien Klin Wochenschr       Date:  2017-04-13       Impact factor: 1.704

Review 2.  Post-stroke inflammatory response: effects of stroke evolution and outcome.

Authors:  Kiat T Tan; Gregory Y H Lip; Andrew D Blann
Journal:  Curr Atheroscler Rep       Date:  2003-07       Impact factor: 5.113

3.  Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.

Authors:  W O Tobin; J A Kinsella; G F Kavanagh; J S O'Donnell; R T McGrath; T Coughlan; D R Collins; D O'Neill; B Egan; S Tierney; T M Feeley; R P Murphy; D J H McCabe
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

Review 4.  von Willebrand factor: an emerging target in stroke therapy.

Authors:  Simon F De Meyer; Guido Stoll; Denisa D Wagner; Christoph Kleinschnitz
Journal:  Stroke       Date:  2011-12-15       Impact factor: 7.914

5.  Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab.

Authors:  Kazuya Sakai; Tatsuhiko Someya; Kaori Harada; Hideo Yagi; Taei Matsui; Masanori Matsumoto
Journal:  Haematologica       Date:  2019-12-19       Impact factor: 9.941

6.  von Willebrand factor/ADAMTS13 ratio at presentation of acute ischemic brain injury is predictive of outcome.

Authors:  Alice Taylor; Chiara Vendramin; Deepak Singh; Martin M Brown; Marie Scully
Journal:  Blood Adv       Date:  2020-01-28

7.  von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.

Authors:  Bing-Qiao Zhao; Anil K Chauhan; Matthias Canault; Ian S Patten; Janie J Yang; Michael Dockal; Friedrich Scheiflinger; Denisa D Wagner
Journal:  Blood       Date:  2009-08-17       Impact factor: 22.113

8.  Prenatal stress-induced increases in hippocampal von Willebrand factor expression are prevented by concurrent prenatal escitalopram.

Authors:  Gretchen N Neigh; Christina L Nemeth; Sean D Kelly; Emily E Hardy; Chase Bourke; Zachary N Stowe; Michael J Owens
Journal:  Physiol Behav       Date:  2016-07-13

9.  Synergistic Effect of AJW200, a von Willebrand Factor Neutralizing Antibody with Low Dose (0.9 mg/mg) Thrombolytic Therapy Following Embolic Stroke in Rabbits.

Authors:  Paul A Lapchak; Sarina Doyan; Xiaomin Fan; Catherine M Woods
Journal:  J Neurol Neurophysiol       Date:  2013-04-01

10.  von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.

Authors:  Stephen J X Murphy; Soon Tjin Lim; Fionnuala Hickey; Justin A Kinsella; Deirdre R Smith; Sean Tierney; Bridget Egan; T Martin Feeley; Sinéad M Murphy; D Rónán Collins; Tara Coughlan; Desmond O'Neill; Joseph A Harbison; Prakash Madhavan; Sean M O'Neill; Mary-Paula Colgan; James S O'Donnell; Jamie M O'Sullivan; George Hamilton; Dominick J H McCabe
Journal:  Thromb Haemost       Date:  2020-09-15       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.